CG Oncology, Inc. (CGON) Market Cap & Valuation Ratios
CG Oncology, Inc. (CGON) has a market cap of $5.5B and a price-to-sales ratio of 878.3, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CGONCG Oncology, Inc.Follow CGON — free
—
Price chart with a free account
- Market cap
- 5.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| CGON | 5.5 | — | 713.7 | — | -3.3% | +1030% | — | -25% |
| LGND | 6.1 | 32.3 | 20.0 | 45.6 | 2.2% | +55% | 33% | 9% |
| IMVT | 5.9 | — | — | — | -6.9% | — | — | — |
| MANE | 5.8 | — | — | — | -1.4% | — | — | -21% |
| KOD | 5.5 | — | — | — | -2.9% | — | — | — |
| COGT | 5.4 | — | 615.8 | — | -5.7% | — | — | -120% |
| ORKA | 5.3 | — | — | — | -1.9% | — | — | -28% |
| MIRM | 5.2 | — | 8.9 | — | -4.4% | +44% | -135% | -224% |
| PTCT | 5.1 | — | 3.4 | 18.9 | -0.8% | -43% | 12% | — |
| SRRK | 5.1 | — | — | — | -5.9% | — | — | -568% |
| ERAS | 5.0 | — | — | — | -1.9% | — | — | -97% |
| Median of these 10 | 32.3 | 14.5 | 32.2 | -2.4% | +44% | 12% | -97% |
; EV/Sales 713.7 vs. 14.5.
Growth vs. price
each dot a company · hover or tap for valuesCG Oncology, Inc. — questions
- What is CG Oncology, Inc.'s market cap?
- $5.5B.
- What is CG Oncology, Inc.'s price-to-sales ratio?
- 878.3.
Every figure on this page comes from CG Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.